Amivantamab-Chemotherapy Combo Shows Promise in Advanced NSCLC Patients with EGFR Exon 20 Insertions
A recent phase 3, international, randomized trial has demonstrated the superior efficacy of amivantamab combined with chemotherapy over chemotherapy alone in treating patients with advanced non-small-cell lung cancer (NSCLC) with EGFR exon 20 insertions. This study provides valuable insights into the potential of amivantamab as a first-line treatment option for this patient population.
- The study involved 308 patients with advanced NSCLC with EGFR exon 20 insertions who had not received previous systemic therapy.
- Patients were randomly assigned in a 1:1 ratio to receive intravenous amivantamab plus chemotherapy (amivantamab–chemotherapy) or chemotherapy alone.
- Patients in the chemotherapy group who had disease progression were allowed to cross over to receive amivantamab monotherapy.
- Progression-free survival was significantly longer in the amivantamab–chemotherapy group than in the chemotherapy group (median, 11.4 months and 6.7 months, respectively).
- At 18 months, progression-free survival was reported in 31% of the patients in the amivantamab–chemotherapy group and in 3% in the chemotherapy group.
- A complete or partial response at data cutoff was reported in 73% and 47%, respectively.
- In the interim overall survival analysis (33% maturity), the hazard ratio for death for amivantamab–chemotherapy as compared with chemotherapy was 0.67.
- The predominant adverse events associated with amivantamab–chemotherapy were reversible hematologic and EGFR-related toxic effects; 7% of patients discontinued amivantamab owing to adverse reactions.
According to the World Health Organization, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.
More on Combination Therapy